Healthcare / Drug Manufacturers - Specialty & GenericBSEIN
$249.95
+0.60 (+0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $1.9B · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$109.1B
P/E
62.5x
↑EV/EBITDA
17.1x
↑ROE
6.1%
↑Gross Margin
54.3%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+34.1%
FCF CAGR
—
FCF margin
5.5%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $34.20B · net income $1.77B · FCF $1.88B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $34.20B | $34.20B | $30.07B | $13.66B | $14.18B |
| Net Income | $1.77B | $1.77B | $232.2M | $-358.7M | $-1.21B |
| EBITDA | $6.52B | $6.52B | $3.38B | $533.2M | $-522.5M |
| EPS | — | — | 0.53 | -1.44 | -4.88 |
| Gross Margin | 54.3% | 54.3% | 51.1% | 40.5% | 36.6% |
| Operating Margin | 12.3% | 12.3% | 4.8% | 2.7% | 0.0% |
| Net Margin | 5.2% | 5.2% | 0.8% | -2.6% | -8.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.68 | 0.74 | 0.63 |
| Current Ratio | 2.38 | 2.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.88B | $1.88B | $2.37B | $-2.1M | $-693.7M |
| Returns | |||||
| ROE | 6.1% | 6.1% | 3.3% | -5.5% | -17.3% |
| Valuation | |||||
| P/E | 62.49 | 62.49 | 252.55 | — | — |
| EV/EBITDA | 17.09 | 17.09 | 11.13 | 69.07 | — |
| P/B | 3.75 | 3.75 | 4.75 | 4.96 | 2.68 |
| Growth & Yield | |||||
| Revenue Growth | 13.8% | 13.8% | 120.1% | -3.7% | — |
| EPS Growth | — | — | 136.8% | 70.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.53 → n/d
Residual
+33.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.